EVT 103

Drug Profile

EVT 103

Alternative Names: ENS 103; EVT103

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Evotec AG
  • Class Antidepressants; Small molecules
  • Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Major depressive disorder

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in Germany (PO)
  • 14 May 2014 Janssen plans to continue development in Major depressive disorders
  • 17 Dec 2012 EVT 103 (including other NR2B selective NMDA antagonists) licensed to Janssen Pharmaceuticals worldwide for Depression
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top